TIVO 1 study shows tivozanib an option for renal cell carcinoma

Share :
Published: 25 Feb 2013
Views: 5490
Rating:
Save
Dr Robert Motzer - Memorial Sloan Kettering Cancer Centre, New York, USA

Dr Motzer talks to ecancer at the 2013 ASCO GU symposium. TIVO 1 study shows tivozanib an option for renal cell carcinoma: Overall Survival from Phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma.